In particular, our results support the utility of therapy targeting extracellular matrix components for HER2-enriched breast cancer, in accordance with previous research reporting that dense extracellular matrix components around the tumor could block trastuzumab (Herceptin) targeting of HER236. This evidence concerns the gene ERBB2 and breast cancer.